Patents by Inventor Samira Kiani

Samira Kiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220325298
    Abstract: Disclosed are effective, specific, and durable pain management therapies using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-based) epigenetic modulation of endogenous pathways involved in pain.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 13, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Samira Kiani, Mo Reza Ebrahimkhani, Tahere Mokhtari
  • Publication number: 20220282219
    Abstract: The present disclosure relates to methods for expanding populations of hematopoietic stem cells (HSCs) using a genetically engineered human fetal liver niche and compositions of purified ex vivo expanded HSCs. Also provided herein are methods of using such expanded HSC cell populations for clinical applications including allogeneic hematopoietic stem cell transplantation and for drug discovery and modeling human liver development.
    Type: Application
    Filed: August 12, 2020
    Publication date: September 8, 2022
    Inventors: Mo Reza Ebrahimkhani, Jeremy Velazquez, Samira Kiani, Ryan Patrick LeGraw
  • Publication number: 20220162574
    Abstract: Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.
    Type: Application
    Filed: December 9, 2021
    Publication date: May 26, 2022
    Inventors: Samira Kiani, Radwa Ewaisha, Shayesteh Roshdi Ferdosi, Karen Anderson, Farzaneh Moghadam, Sri Krishna, Mohammad R Ebrahimkhani
  • Patent number: 11208640
    Abstract: Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 28, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Radwa Ewaisha, Samira Kiani, Shayesteh Roshdi Ferdosi, Karen Anderson, Farzaneh Moghadam, Sri Krishna, Mo Reza Ebrahimkhani
  • Publication number: 20210380990
    Abstract: Provided herein are CRISPR-based synthetic repression systems as well as methods and compositions using the synthetic repression systems to treat septicemia, an adverse immune response in a subject and Waldanstrom macroglobulinemia.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 9, 2021
    Inventors: Samira KIANI, Mo Reza EBRAHIMKHANI, Farzaneh MOGHADAM
  • Publication number: 20210254012
    Abstract: The present disclosure relates to synthetic liver organoids and methods of using such synthetic liver organoids for various applications including drug discovery and modeling human liver development. In particular, provided herein are methods of producing and using synthetic mature liver organoids comprising mature, functional cells found in the human liver.
    Type: Application
    Filed: June 10, 2019
    Publication date: August 19, 2021
    Inventors: Samira Kiani, Mo Reza Ebrahimkhani, Jeremy Velazquez, Ryan LeGraw, Patrick Cahan
  • Patent number: 11041154
    Abstract: Provided herein are tools for understanding and engineering dynamics of synthetic genetic circuits which utilize CRISPR components. More particularly, methods, systems, and compositions for directing Cas9 activity using a fluorescent guide RNA (fgR-NA) which fluoresces in the presence of small molecules (e.g., DFHBI-IT) are described and illustrated in the present provisional application.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: June 22, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Samira Kiani, Xiao Wang, David Menn, Mo Reza Ebrahimkhani
  • Publication number: 20210155954
    Abstract: Aspects of the disclosure relate to synthetic regulatory systems composed of a multifunctional Cas nuclease, at least two guide RNAs (gRNAs) configured to target distinct nucleotide sequences, and a multilayered regulatory control element comprising ribozyme-based safety switches providing spatial and temporal control over the synthetic circuit in vivo.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 27, 2021
    Inventors: Samira Kiani, Mo Reza Ebrahimkhani, Swechchha Pradhan, Farzaneh Moghadam
  • Publication number: 20210154326
    Abstract: Aspects of the disclosure relate to synthetic regulatory systems comprising a multifunctional Cas nuclease and at least two guide RNAs (gRNAs) including a truncated gRNA and an multilayered regulatory control element. The synthetic regulatory system modulates endogenous gene expression, including transcriptional repression and transcriptional activation of one or more endogenous genes of a mammalian inner ear cell with multiple safety switches. Also provided herein are methods for modulating hearing sensitivity in damaged cells of the organ of corti.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 27, 2021
    Inventors: Samira Kiani, Swechchha Pradhan, Farzaneh Moghadam, Mo Reza Ebrahimkhani
  • Publication number: 20200377884
    Abstract: Provided herein are tools for understanding and engineering dynamics of synthetic genetic circuits which utilize CRISPR components. More particularly, methods, systems, and compositions for directing Cas9 activity using a fluorescent guide RNA (fgR-NA) which fluoresces in the presence of small molecules (e.g., DFHBI-IT) are described and illustrated in the present provisional application.
    Type: Application
    Filed: September 29, 2017
    Publication date: December 3, 2020
    Inventors: Samira Kiani, Xiao Wang, David Menn, Mo Reza Ebrahimkhani
  • Publication number: 20200377871
    Abstract: Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.
    Type: Application
    Filed: April 27, 2018
    Publication date: December 3, 2020
    Inventors: Radwa Ewaisha, Samira Kiani, Shayesteh Roshdi Ferdosi, Karen Anderson, Farzaneh Moghadam, Sri Krishna, Mo Reza Ebrahimkhani
  • Publication number: 20200123567
    Abstract: Aspects of the disclosure relate to methods and synthetic regulatory systems for more efficient nuclease-mediated homology-directed repair (HDR). In particular, provided herein are methods for more efficient in vivo and in vitro HDR-based gene editing where the methods comprise introducing into a cell a synthetic regulatory system comprising Cas nuclease, guide RNAs (gRNAs) having various lengths and configured to target distinct nucleotide sequences for simultaneous transcriptional repression (or activation) and genome editing via double stranded break and use of a donor nucleic acid molecule as a template for repair.
    Type: Application
    Filed: June 26, 2018
    Publication date: April 23, 2020
    Inventors: Samira Kiani, Mohammed R Ebrahimkhani, Jennifer Chapman
  • Publication number: 20180251789
    Abstract: Aspects of the disclosure relate to synthetic regulatory systems composed of a multifunctional clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) nuclease and at least two distinct guide RNAs (gRNAs). The synthetic regulatory system modulates cleavage and transcription, including repression and activation, in a mammalian cell such as a human cell.
    Type: Application
    Filed: September 1, 2016
    Publication date: September 6, 2018
    Applicant: Massachusetts Institute of Technology
    Inventors: Samira Kiani, Ron Weiss, Mohammad Reza Ebrahimkhani
  • Publication number: 20160326546
    Abstract: Provided herein, in some embodiments, are modular transcriptional architectures and methods for regulated expression of guide RNAs in cells, such as human cells, which are based on Clustered Regularly Interspaced Palindromic Repeats (CRISPR) systems.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 10, 2016
    Applicants: Massachusetts Institute of Technology, Raytheon BBN Technologies, Corp.
    Inventors: Samira Kiani, Ron Weiss, Jacob S. Beal, Mohammad Reza Ebrahimkhani, Zhen Xie, Yinqing Li